Next-Generation Phosphorothioate-conjugated miRNAs for Personalized Medicine

A novel, next-generation technology for treating multiple myeloma and other diseases using phosphorothioate-conjugated miRNAs, incorporating advanced delivery systems, personalized medicine approaches, and real-time monitoring capabilities.

The original patent disclosed phosphorothioate-conjugated miRNAs for treating multiple myeloma, but it had limitations in terms of delivery, efficacy, and patient specificity. The new inventive concept addresses these limitations by introducing nanoparticle-based delivery, personalized medicine approaches, and real-time monitoring capabilities, enabling more effective and targeted treatment of diseases.

The next-generation technology comprises a nucleic acid conjugate with a microRNA selected from the group consisting of let7a-3p miRNA, let7a-5p miRNA, miR17-3p miRNA, miR17-5p miRNA, and miR218-5p miRNA. The conjugate is delivered via a nanoparticle with a tunable release profile, allowing for controlled and sustained release of the microRNA. Additionally, the technology incorporates a device for monitoring treatment efficacy and a bioinformatics tool for predicting treatment outcomes, enabling personalized medicine approaches. The system also includes a composition of matter comprising a nucleic acid conjugate with a microRNA and a polymer matrix with tunable biodegradability, which is implantable and releases the conjugate in a controlled manner.

The new claims introduce several novel and non-obvious features, including nanoparticle-based delivery, personalized medicine approaches, and real-time monitoring capabilities, which are not present in the original patent. The combination of these features enables a more effective and targeted treatment of diseases, which is not obvious from the original patent.

Alternative embodiments of the inventive concept could include different types of nanoparticles, such as liposomes or dendrimers, or different polymer matrices with varying biodegradability profiles. Additionally, the technology could be adapted for use with different microRNAs or nucleic acid conjugates, or for treating different diseases.

The next-generation technology has significant commercial potential in the treatment of multiple myeloma and other diseases, particularly in the context of personalized medicine. The technology could be licensed to pharmaceutical companies or used to develop new products and services in the healthcare industry.